Sunshine Biopharma, Inc.
SBFMNASDAQHealthcare● Active
$2.43
$-0.03(-1.22%)
Market Cap$1216409
P/E Ratio—
52W High$24.3
52W Low$2.11
Sunshine Biopharma, Inc. (SBFM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SBFM · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 4, 2026EPS Actual
-$2.50
Est. -$2.50 · +0.0%
Revenue
$0.01B
Est. $0.01B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 4, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
SBFM reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$1.20 | — | — | — | $0.01B | — |
| — Q2 FY2026 | Apr 4, 2026 | -$2.50 | -$2.50 | +0.0% | $0.01B | $0.01B | +0.0% |
| ▼ Q2 FY2026 | Apr 3, 2026 | -$2.70 | -$3.00 | -11.1% | $0.01B | $0.01B | -14.0% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.13 | -$0.19 | -46.1% | $0.01B | $0.01B | -15.2% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.11 | -$0.39 | -254.6% | $0.01B | $0.01B | -16.0% |
| — Q2 FY2025 | May 15, 2025 | — | -$0.44 | — | $0.01B | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | $0.01 | -$1.01 | -10200.0% | $0.01B | $0.01B | -23.3% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$535.00 | -$0.94 | +99.8% | $0.01B | $0.01B | -28.5% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$1.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 4, 2026
EPS Actual
-$2.50
EPS Est.
-$2.50
EPS Surpr.
+0.0%
Revenue
$0.01B
Q2 FY2026
Apr 3, 2026Miss
EPS Actual
-$3.00
EPS Est.
-$2.70
EPS Surpr.
-11.1%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.13
EPS Surpr.
-46.1%
Revenue
$0.01B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.39
EPS Est.
-$0.11
EPS Surpr.
-254.6%
Revenue
$0.01B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.44
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$1.01
EPS Est.
$0.01
EPS Surpr.
-10200.0%
Revenue
$0.01B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.94
EPS Est.
-$535.00
EPS Surpr.
+99.8%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.30 | $-1.30 | $-1.30 | 1 |
| Q3 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q2 FY2026 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q1 FY2026 | $-2.50 | $-2.50 | $-2.50 | 1 |
| Q4 FY2025 | $-2.70 | $-2.70 | $-2.70 | 1 |
| Q3 FY2025 | $-1.30 | $-1.30 | $-1.30 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 4, 2026 | +0.0% | $10.40 | $11.60 | +11.54% |
| ▼ Q2 FY2026 | Apr 3, 2026 | -11.1% | $10.40 | $11.60 | +11.54% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -46.1% | $17.70 | $16.70 | -5.65% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -254.6% | $14.30 | $14.20 | -0.70% |
| — Q2 FY2025 | May 15, 2025 | — | $13.90 | $13.20 | -5.04% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -10200.0% | $20.00 | $19.10 | -4.50% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +99.8% | $28.90 | $28.60 | -1.04% |
| ▼ Q3 FY2024 | Aug 19, 2024 | -1556.7% | $29.20 | $30.90 | +5.82% |
Q2 FY2026+11.54%
Report Date
Apr 4, 2026
EPS Beat/Miss
+0.0%
Price Before
$10.40
Price After
$11.60
Q2 FY2026+11.54%
Report Date
Apr 3, 2026
EPS Beat/Miss
-11.1%
Price Before
$10.40
Price After
$11.60
Q4 FY2025-5.65%
Report Date
Nov 13, 2025
EPS Beat/Miss
-46.1%
Price Before
$17.70
Price After
$16.70
Q3 FY2025-0.70%
Report Date
Aug 12, 2025
EPS Beat/Miss
-254.6%
Price Before
$14.30
Price After
$14.20
Q2 FY2025-5.04%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$13.90
Price After
$13.20
Q1 FY2025-4.50%
Report Date
Mar 31, 2025
EPS Beat/Miss
-10200.0%
Price Before
$20.00
Price After
$19.10
Q4 FY2024-1.04%
Report Date
Nov 5, 2024
EPS Beat/Miss
+99.8%
Price Before
$28.90
Price After
$28.60
Q3 FY2024+5.82%
Report Date
Aug 19, 2024
EPS Beat/Miss
-1556.7%
Price Before
$29.20
Price After
$30.90
Avg Beat Reaction+5.25%
Avg Miss Reaction+1.30%
Beat Rate2 / 8 quarters
Largest Move+11.54% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SBFM ends December
Sunshine Biopharma, Inc. (SBFM) most recently reported earnings on April 4, 2026 for Q2 FY2026, posting EPS of $-2.50 (in line with the analyst consensus of $-2.50). The next SBFM earnings date is expected around September 1, 2026.
Each quarter, investors track SBFM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SBFM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SBFM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SBFM earnings · 4 questionsSunshine Biopharma, Inc.'s next earnings report is expected around September 1, 2026. SBFM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SBFM historically reports after market close (AMC).
SBFM earnings datewhen is SBFM earningsSBFM next earnings datewhen does SBFM report earningsSBFM earnings calendar
▸ Source: FMP · Sunshine Biopharma, Inc. SEC filings · US GAAP · Sunshine Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026